Biomedica Molecular Medicine

With clinician needs and patient wellbeing at the foremost of what we do Biomedica Molecular Medicine emerges from clinical research, working in collaboration with clinicians and pharmaceutical companies to address key questions for the improvement of healthcare outcomes. BioBreast Breast cancer is by far the most common cancer diagnosed in women worldwide, with an estimated 1.38 million new cases diagnosed in 2008. A key area in the management of early breast cancer is the selection of complementary therapy after surgery, which depends on the use of prognostic and predictive factors. At present, oncologists decide whether to prescribe chemotherapy using clinical and biological criteria. Patients who are predicted to have a high likelihood of developing metastatic disease are advised to receive chemotherapy. Clinicians increasingly rely on profiling tests to make decisions on appropriate treatments, and the clinical trend is to personalize therapies according to molecular profiles. We have developed BioBreast, a prognostic platform for early-stage breast cancer. BioBreast comprises three different tests, developed independently, increasing the accuracy in treatment decision. miRScore Renal cell carcinoma (RCC) is one of the most common adult malignancy in Europe, with more than 115,000 new cases diagnosed (3% of the total) and 49,000 kidney cancer related deaths in 2012. We have developed an expression profiling tool based on specific miRNAs; we have called it miRNAscore. The preliminary studies reveal a very promising improvement of the predictive accuracy regarding to current prognostic systems. Furthermore, our score avoids the existence of an intermediate risk group, stratifying all patients in either low or high risk levels. This is quite important for clinical practice, since intermediary groups do not allow for effective decision-making.